ReviewOncology letters2025
Abnormal metabolic networks participate in invasion and migration of tumors of the digestive system (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digestive system neoplasms are the most common malignant tumor worldwide. Tumor metastasis is also an important factor in tumor-related mortality. Deregulation of cellular metabolism is as a major indicator of cancer, and reprogramming of metabolism is thought to be necessary to meet the increased energy demands of tumors. Reprogramming of the metabolism is crucial for the spread of tumors. The present review summarizes the role of enzymes and molecules involved in abnormal metabolism in digestive system neoplasms and their crosstalk with oncogenic signaling pathways in tumor metastasis. Elucidation of the network regulating metabolic reprogramming of cancer may identify novel cancer therapies, which may improve the poor prognosis of patients with cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.